Refractory polymyositis responding in infliximab: Extended follow-up [8]

Rheumatology

Volumn 43, Issue 4, 2004, Pages 531-532

  Labioche, L ^b   Liozon, Eric ^b,c   Weschler, B ^a   Loustaud Ratti, V ^b   Soria, P ^b   Vidal, E ^b  

^a University Hospital   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; ELECTROMYOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LETTER; MUSCLE BIOPSY; OUTCOMES RESEARCH; PHYSICAL EXAMINATION; POLYMYOSITIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; POLYMYOSITIS;

EID: 1842844282     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh079     Document Type: Letter

References (10)

1. Joffe MM, Love LA, Leff RL et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and comparison of their efficacy. Am J Med 1993;94:379-87.
2. Cherin P. Recognition and management of myositis. Drugs 1997; 54:39-49.
3. Hengstman G, Van Den Hooven F, Van Egelen B, Barreta P, Netea M. Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis. Arthritis Rheum 2000;43:S193.
4. Lundberg IE, Nyberg P. New developments in the role of cytokines in inflammatory myopathies. Curr Opin Rheumatol 1998;10: 521-9.
5. Kuru S, Inukai A, Liang Y, Doyu M, Tkano A, Sobue G. Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol (Berl) 2000;99:585-8.
6. Prieur AM, Dayer A, Roux-Lombard P, Dayer JM. Levels of cytokine inhibitors: a possible marker of disease activity in childhood dermatomyositis and polymyositis. Clin Exp Rheumatol 1997; 15: 211-4.
7. Werth VP, Callen JP, Sullivan KE. Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 2002; 119: 617-20.
8. Saadeh CK. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroid and other disease modifying agents. Arthritis Rheum 2000;43:S193.
9. Hengstman GJD, Van Den Hoogen FHJ, Barbera P et al. Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis. Eur Neurol 2003;50:10-5.
10. Roddy E, Courtney PA, Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which has been treated with infliximab. Rheumatology 2002;41:1194-5.